FDA Approved Products

523 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Type: BLAClear all
A.P.L.
gonadotropin, chorionic
LOE Approaching
Ferring Pharmaceuticals
INJECTION · INJECTABLE
1974
BLA
30/100
ABRILADA
adalimumab-afzb
Peak
Pfizer
INJECTION · INJECTABLE
moderately to severely active Crohn's disease in adultsolder+11
2019
BLA
30/100
ACCRETROPIN
somatropin
LOE Approaching
Emergent BioSolutions
INJECTION · INJECTABLE
short stature associated with Turner syndromeidiopathic short stature (ISS)+1
2008
BLA
30/100
ACTEMRA
tocilizumab
LOE Approaching
Roche
INJECTION · INJECTABLE
more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)giant cell arteritis (GCA) in adult patients+11
2010
mAbBLA
30/100
ACTEMRA
tocilizumab
Peak
Roche
INTRAVENOUS, SUBCUTANEOUS · INJECTABLE
more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)giant cell arteritis (GCA) in adult patients+11
2013
mAbBLA
30/100
ACTHREL
corticorelin ovine triflutate
LOE Approaching
Ferring Pharmaceuticals
INJECTION · INJECTABLE
1996
BLA
30/100
ACTIMMUNE
interferon gamma-1b
LOE Approaching
Amgen
SINGLE-USE · VIAL
1999
BLA
30/100
ACTIVASE
alteplase
LOE Approaching
Roche
SINGLE-USE · VIAL
1987
BLA
30/100
ADAGEN
pegademase bovine
LOE Approaching
Leadiant Biosciences
INJECTION · INJECTABLE
1990
BLA
30/100
ADAKVEO
crizanlizumab
Peak
Novartis
INJECTION · INJECTABLE
frequency of vasoocclusive crises in adultsolder with sickle cell disease
2019
mAbBLA
30/100
ADBRY
tralokinumab-ldrm
Peak
Leo Pharma
INJECTION · INJECTABLE
moderate-to-severe atopic dermatitis in adultsolder whose disease is not adequately controlled with topical prescription therapies+2
2021
BLA
30/100
ADCETRIS
brentuximab vedotin
Peak
Pfizer
INJECTION · INJECTABLE
IV cHLcombination with doxorubicin+23
2011
ADCBLA
30/100
ADCETRIS
brentuximab vedotin
Peak
Pfizer
INJECTION · INJECTABLE
IV cHLcombination with doxorubicin+23
2011
ADCBLA
30/100
ADLYXIN
lixisenatide
Peak
Sanofi
SUBCUTANEOUS · SOLUTION
type 2 diabetes mellitus
2016
PeptideBLA
30/100
ADMELOG
insulin lispro
Peak
Sanofi
INTRAVENOUS, SUBCUTANEOUS · SOLUTION
glycemic control in adult
2017
BLA
30/100
ADMELOG SOLOSTAR
insulin lispro
Peak
Sanofi
SUBCUTANEOUS · SOLUTION
glycemic control in adult
2017
BLA
30/100
ADUHELM
aducanumab-avwa
Peak
Biogen
INJECTION · INJECTABLE
2021
BLA
30/100
AFREZZA
insulin human
Peak
INHALATION · POWDER
glycemic control in adult patients with diabetes mellitus
2014
BLA
30/100
AHZANTIVE
aflibercept-mrbb
Growth
Formycon
INJECTION · INJECTABLE
Macular Degeneration
2024
BLA
30/100
AIMOVIG
erenumab-aooe
Peak
Amgen
INJECTION · INJECTABLE
migraine
2018
BLA
30/100
AJOVY
fremanezumab-vfrm
Peak
Teva
INJECTION · INJECTABLE
migraine
2018
BLA
30/100
ALDURAZYME
laronidase
LOE Approaching
BioMarin Pharmaceutical
INTRAVENOUS · VIAL
Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I)for the treatment of patients with the Scheie form of MPS I
2003
BLA
30/100
ALFERON N INJECTION
interferon alfa-n3
LOE Approaching
VIAL
1989
BLA
30/100
ALHEMO
concizumab
Growth
Novo Nordisk
Subcutaneous · Injectable
2024
mAbBLA
30/100
Page 1 of 22Next →